They discovered that CD73 inhibition improved the anti-tumor functions of Tregs and exhausted CD8+ T cells distinctly from PD-1 inhibition, showing that the combination of CD73 inhibitors and PD-1 inhibitors could synergistically kill cancer cells in CRC treatment. This evidence concerns the gene NT5E and colorectal carcinoma.